 | |||||||||
-
MindBio Co-Founder Justin Hanka and scientific collaborators to present Phase 1 Microdosing LSD Clinical Trial data in Miami on November 4th 2022
Vancouver, British Columbia – TheNewswire - Sept 15, 2022 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its wholly-owned subsidiary, MindBio Therapeutics (“MindBio”), will be presenting its Phase 1 clinical trial data from its LSD (Lysergic Acid Diethylamide) Microdosing studies in Miami on November 4th 2022 at the Wonderland Convention, the world’s largest psychedelics event.
MindBio is a clinical stage drug development company creating a safe and effective microdosing treatment protocol using psychedelic medicines to treat mental health conditions. MindBio’s clinical trials have the unique advantage of having regulatory approvals for clinical trial participants to take their microdoses of LSD out in the community and at home in the same way they would take any other medicine. MindBio remains the only organisation in the world to have clinical trials running with this kind of regulatory approval for clinical trial participants to take LSD in microdoses outside of the laboratory.
Microdosing involves taking repeated small doses of a psychedelic medicine (in this case LSD), where a microdose is subperceptual and the drug’s effects are non-hallucinogenic.
The Phase 1 clinical trials involved a randomized double masked and placebo-controlled administration of LSD or placebo in 80 healthy participants.
MindBio wants to be first to market with a microdosing regimen and predictive treatment protocol for microdosing psychedelic medicines with the potential to:
-
have potential lower side effect risk profile to existing pharmacological treatments such as anti-depressants and benzodiazapines for the treatment of a range of mental health conditions;
-
offer less risk of harm and disruption to daily activity than large, one off doses of psychedelics;
-
affect brain neuroplasticity after acute administration, in the same way that larger hallucinogenic doses affect the brain, yet the patient is still able to get on with their normal day after ingesting the microdose. This is not possible with a psychedelic macro-dosing treatment session which requires an in clinic therapeutic session guided by clinicians over many hours.
-
is a scalable solution to global mental health treatment.
The results of this important clinical trial will form the basis for advancing two separate Phase 2 clinical trials in patients with Major Depressive Disorder and in patients with late stage cancer suffering emotional distress. Both Phase 2 clinical trials are currently in development.
“We are very pleased to have completed Phase 1 clinical trials and are looking forward to progressing our commercialization agenda” said Frederick Pels, CEO of Blackhawk.
MindBio is planning to spin out of Blackhawk and list on the Canadian Securities Exchange and preparations are progressing after some delay. MindBio is hoping to make further announcements on the timing on the spin out shortly.
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, Spaced Food, Stable Foods, Digital Mind Therapeutics, Blum Distributors Ltd. and MindBio Therapeutics.
The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.